ZB Zenas BioPharma, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Zenas BioPharma, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €2bn. The latest transaction was disclosed on 29 April 2026 (Acquisition). Among the most active insiders: MOULDER LEON O JR. All data is free.
Analyst consensus: bullish or bearish? Analysts rate Zenas BioPharma, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$47.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 April 2026
All Executives33 Thresholds0 Prospectus0 Other0
Declarations 33 total
▲ Chief Executive Officer · Executives · 28 Apr 2026
25,000 shares @ US$18.02 0.038% mcap 24.1% of flow Common Stock SEC:0001104659-26-051889:0
Canonical exit: 27 Jul 2026 (T+90) ▲ Chief Executive Officer · Executives · 29 Apr 2026
35,000 shares @ US$17.62 0.052% mcap 33.1% of flow Common Stock SEC:0001104659-26-051889:1
Canonical exit: 28 Jul 2026 (T+90) ▲ Director · Executives · 31 Mar 2026
3,768 shares @ US$18.63 6.3% of flow Common Stock SEC:0001104659-26-039240:0
Canonical exit: 29 Jun 2026 (T+90) ▲ Director · Executives · 31 Mar 2026
150,000 shares @ US$20.00 100.0% of flow Common Stock SEC:0001104659-26-038546:0
Canonical exit: 29 Jun 2026 (T+90) ▲ Director · Executives · 31 Mar 2026
75,000 shares @ US$20.00 57.4% of flow Common Stock SEC:0001104659-26-037865:0
Canonical exit: 29 Jun 2026 (T+90) ▲ Chief Executive Officer · Executives · 30 Mar 2026
20,000 shares @ US$18.23 12.8% of flow Common Stock SEC:0001104659-26-038031:0
Canonical exit: 28 Jun 2026 (T+90) ▲ Chief Executive Officer · Executives · 31 Mar 2026
34,000 shares @ US$19.31 22.9% of flow Common Stock SEC:0001104659-26-038031:1
Canonical exit: 29 Jun 2026 (T+90) ▲ Director · Executives · 11 Feb 2026
25,985 shares @ US$22.50 13.5% of flow Common Stock SEC:0001104659-26-015387:0
Canonical exit: 12 May 2026 (T+90) ▲ Director · Executives · 12 Feb 2026
5,000 shares @ US$23.77 100.0% of flow Common Stock SEC:0001104659-26-015342:0
Canonical exit: 13 May 2026 (T+90) ▲ Chief Executive Officer · Executives · 2 Feb 2026
57,000 shares @ US$17.96 18.4% of flow Common Stock SEC:0001104659-26-009756:0
Canonical exit: 3 May 2026 (T+90) ▲ Chief Executive Officer · Executives · 7 Jan 2026
50,000 shares @ US$16.38 14.9% of flow Common Stock SEC:0001104659-26-002589:0
Canonical exit: 7 Apr 2026 (T+90) ▲ Director · Executives · 9 Oct 2025
63,158 shares @ US$19.00 100.0% of flow Common Stock SEC:0001193125-25-239158:0
Canonical exit: 7 Jan 2026 (T+90) 63,158 shares @ US$19.00 100.0% of flow Common Stock SEC:0001193125-25-239153:0
Canonical exit: 7 Jan 2026 (T+90) ▲ Director · Executives · 9 Oct 2025
105,265 shares @ US$19.00 100.0% of flow Common Stock SEC:0001193125-25-238326:0
Canonical exit: 7 Jan 2026 (T+90) ▲ Director · Executives · 13 Sept 2024
58,823 shares @ US$17.00 28.5% of flow Common Stock SEC:0000919574-25-006031:0
Canonical exit: 12 Dec 2024 (T+90) ▲ See Remarks · Executives · 7 Oct 2025
36,928 shares @ US$20.85 21.0% of flow Common Stock SEC:0001104659-25-098413:0
Canonical exit: 5 Jan 2026 (T+90) ▲ Director · Executives · 7 Oct 2025
316,219 shares @ US$19.00 66.5% of flow Common Stock SEC:0001104659-25-098362:0
Canonical exit: 5 Jan 2026 (T+90) ▲ Director · Executives · 7 Feb 2025
10,000 shares @ US$7.76 50.0% of flow Common Stock SEC:0001104659-25-039771:0
Canonical exit: 8 May 2025 (T+90) ▲ Chief Executive Officer · Executives · 18 Feb 2025
25,000 shares @ US$6.67 23.3% of flow Common Stock SEC:0001104659-25-015145:0
Canonical exit: 19 May 2025 (T+90) ▲ Director · Executives · 7 Feb 2025
10,000 shares @ US$7.76 50.0% of flow Common Stock SEC:0001104659-25-011505:0
Canonical exit: 8 May 2025 (T+90) ▲ Chief Executive Officer · Executives · 3 Dec 2024
25,000 shares @ US$10.76 37.5% of flow Common Stock SEC:0001104659-24-125677:0
Canonical exit: 3 Mar 2025 (T+90) ▲ Chief Executive Officer · Executives · 18 Nov 2024
7,500 shares @ US$15.00 15.6% of flow Common Stock SEC:0001104659-24-121081:0
Canonical exit: 16 Feb 2025 (T+90) ▲ Chief Executive Officer · Executives · 18 Sept 2024
10,000 shares @ US$17.91 23.6% of flow Common Stock SEC:0001104659-24-101773:0
Canonical exit: 17 Dec 2024 (T+90) 2,879,006 shares Common Stock SEC:0001415889-24-023609:0
180,635 shares Common Stock SEC:0001104659-24-101030:0
25 of 33 declarations
Load more (8 remaining) 关于 Zenas BioPharma, Inc. Zenas BioPharma, Inc. 是一家生物制药公司，专注于开发自身免疫疾病和免疫相关疾病的创新疗法。该公司在XNAS市场上市。